Exploratory secondary analysis of 170 patients from the GOG281/LOGS trial in recurrent low-grade serous ovarian carcinoma: high tumour pERK was associated with longer PFS with trametinib vs standard care (median 20.1 vs 5.6 months).
Secondary analysisn = 170
Hollis et al. Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma